Initial chemoimmunotherapy in inflammatory carcinoma of the breast
Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5‐fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermogr...
Gespeichert in:
| Veröffentlicht in: | Cancer 1982-04, Vol.49 (8), p.1537-1543 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1543 |
|---|---|
| container_issue | 8 |
| container_start_page | 1537 |
| container_title | Cancer |
| container_volume | 49 |
| creator | Zylberberg, B. Salat‐Baroux, J. Ravina, J. H. Dormont, D. Amiel, J. P. Diebold, P. Izrael, V. |
| description | Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5‐fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermographic cooling was taken as the criterion of operability. Initial chemotherapy was resumed after surgery up to a total of ten courses and followed by maintenance chemotherapy for a minimum of one year. Immunotherapy using I‐BCG‐F. Pasteur was routinely associated with the antimitotic agents. The median survival for our 15 patients has not been reached and exceeds 56 months. These results correspond to an obvious therapeutic benefit compared with recent attempts in which similar chemoimmunotherapy protocols were used; this benefit seems to be the consequence of the adaptation of the length of initial chemotherapy to the data given by plate‐thermography. |
| doi_str_mv | 10.1002/1097-0142(19820415)49:8<1537::AID-CNCR2820490805>3.0.CO;2-E |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74010310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74010310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3315-20bc483d6024c12028beaf057372635758998c1f6171a659606ead0d8798aff3</originalsourceid><addsrcrecordid>eNqVUV2LE0EQHMTjjKc_Qdgn0YfN9XzPRBHONZ6Bw4Dcg-BDM9nMcCs7u3Fmg-Tfu0vigT4oBw3NUDXV3VWEVBTmFIBdUrC6BCrYK2oNA0Hla2EX5i2VXC8WV6sPZfW5-sImyIIB-Y7PYV6t37By-YjM7n8_JjMAMKUU_OsT8jTn7-NTM8nPybkGpYyiM_J-1TVD49qivvOxb2Lcd_1w55PbHYqmGyu0LkY39OlQ1C7VTddHV_ShGEnFJnmXh2fkLLg2--enfkFuPy5vq0_lzfp6VV3dlDXnVJYMNrUwfKuAiZoyYGbjXQCpuWaKSy2NtaamQVFNnZJWgfJuC1ujrXEh8Avy8ii7S_2Pvc8DxibXvm1d5_t9Ri2AAh_rf0QqhR2vn4jfjsQ69TknH3CXmujSASnglAROXuLkJf5OAoVFg1MSiGMS-GcSyBGwWiPD5aj-4rTGfhP99l77ZP2IhyP-s2n94WGj_zn5L4T_AkbLpMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15496680</pqid></control><display><type>article</type><title>Initial chemoimmunotherapy in inflammatory carcinoma of the breast</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Zylberberg, B. ; Salat‐Baroux, J. ; Ravina, J. H. ; Dormont, D. ; Amiel, J. P. ; Diebold, P. ; Izrael, V.</creator><creatorcontrib>Zylberberg, B. ; Salat‐Baroux, J. ; Ravina, J. H. ; Dormont, D. ; Amiel, J. P. ; Diebold, P. ; Izrael, V.</creatorcontrib><description>Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5‐fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermographic cooling was taken as the criterion of operability. Initial chemotherapy was resumed after surgery up to a total of ten courses and followed by maintenance chemotherapy for a minimum of one year. Immunotherapy using I‐BCG‐F. Pasteur was routinely associated with the antimitotic agents. The median survival for our 15 patients has not been reached and exceeds 56 months. These results correspond to an obvious therapeutic benefit compared with recent attempts in which similar chemoimmunotherapy protocols were used; this benefit seems to be the consequence of the adaptation of the length of initial chemotherapy to the data given by plate‐thermography.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19820415)49:8<1537::AID-CNCR2820490805>3.0.CO;2-E</identifier><identifier>PMID: 7066861</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject><![CDATA[Aged ; Antineoplastic Agents - administration & dosage ; BCG Vaccine - administration & dosage ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Carcinoma - drug therapy ; Carcinoma - pathology ; Carcinoma - surgery ; Doxorubicin - administration & dosage ; Drug Evaluation ; Drug Therapy, Combination ; Fluorouracil - administration & dosage ; Humans ; Melphalan - administration & dosage ; Methotrexate - administration & dosage ; Middle Aged ; Thermography ; Time Factors ; Vincristine - administration & dosage]]></subject><ispartof>Cancer, 1982-04, Vol.49 (8), p.1537-1543</ispartof><rights>Copyright © 1982 American Cancer Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3315-20bc483d6024c12028beaf057372635758998c1f6171a659606ead0d8798aff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7066861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zylberberg, B.</creatorcontrib><creatorcontrib>Salat‐Baroux, J.</creatorcontrib><creatorcontrib>Ravina, J. H.</creatorcontrib><creatorcontrib>Dormont, D.</creatorcontrib><creatorcontrib>Amiel, J. P.</creatorcontrib><creatorcontrib>Diebold, P.</creatorcontrib><creatorcontrib>Izrael, V.</creatorcontrib><title>Initial chemoimmunotherapy in inflammatory carcinoma of the breast</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5‐fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermographic cooling was taken as the criterion of operability. Initial chemotherapy was resumed after surgery up to a total of ten courses and followed by maintenance chemotherapy for a minimum of one year. Immunotherapy using I‐BCG‐F. Pasteur was routinely associated with the antimitotic agents. The median survival for our 15 patients has not been reached and exceeds 56 months. These results correspond to an obvious therapeutic benefit compared with recent attempts in which similar chemoimmunotherapy protocols were used; this benefit seems to be the consequence of the adaptation of the length of initial chemotherapy to the data given by plate‐thermography.</description><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>BCG Vaccine - administration & dosage</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - surgery</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Evaluation</subject><subject>Drug Therapy, Combination</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Melphalan - administration & dosage</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Thermography</subject><subject>Time Factors</subject><subject>Vincristine - administration & dosage</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUV2LE0EQHMTjjKc_Qdgn0YfN9XzPRBHONZ6Bw4Dcg-BDM9nMcCs7u3Fmg-Tfu0vigT4oBw3NUDXV3VWEVBTmFIBdUrC6BCrYK2oNA0Hla2EX5i2VXC8WV6sPZfW5-sImyIIB-Y7PYV6t37By-YjM7n8_JjMAMKUU_OsT8jTn7-NTM8nPybkGpYyiM_J-1TVD49qivvOxb2Lcd_1w55PbHYqmGyu0LkY39OlQ1C7VTddHV_ShGEnFJnmXh2fkLLg2--enfkFuPy5vq0_lzfp6VV3dlDXnVJYMNrUwfKuAiZoyYGbjXQCpuWaKSy2NtaamQVFNnZJWgfJuC1ujrXEh8Avy8ii7S_2Pvc8DxibXvm1d5_t9Ri2AAh_rf0QqhR2vn4jfjsQ69TknH3CXmujSASnglAROXuLkJf5OAoVFg1MSiGMS-GcSyBGwWiPD5aj-4rTGfhP99l77ZP2IhyP-s2n94WGj_zn5L4T_AkbLpMw</recordid><startdate>19820415</startdate><enddate>19820415</enddate><creator>Zylberberg, B.</creator><creator>Salat‐Baroux, J.</creator><creator>Ravina, J. H.</creator><creator>Dormont, D.</creator><creator>Amiel, J. P.</creator><creator>Diebold, P.</creator><creator>Izrael, V.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19820415</creationdate><title>Initial chemoimmunotherapy in inflammatory carcinoma of the breast</title><author>Zylberberg, B. ; Salat‐Baroux, J. ; Ravina, J. H. ; Dormont, D. ; Amiel, J. P. ; Diebold, P. ; Izrael, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3315-20bc483d6024c12028beaf057372635758998c1f6171a659606ead0d8798aff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>BCG Vaccine - administration & dosage</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - surgery</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Evaluation</topic><topic>Drug Therapy, Combination</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Melphalan - administration & dosage</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Thermography</topic><topic>Time Factors</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zylberberg, B.</creatorcontrib><creatorcontrib>Salat‐Baroux, J.</creatorcontrib><creatorcontrib>Ravina, J. H.</creatorcontrib><creatorcontrib>Dormont, D.</creatorcontrib><creatorcontrib>Amiel, J. P.</creatorcontrib><creatorcontrib>Diebold, P.</creatorcontrib><creatorcontrib>Izrael, V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zylberberg, B.</au><au>Salat‐Baroux, J.</au><au>Ravina, J. H.</au><au>Dormont, D.</au><au>Amiel, J. P.</au><au>Diebold, P.</au><au>Izrael, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial chemoimmunotherapy in inflammatory carcinoma of the breast</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1982-04-15</date><risdate>1982</risdate><volume>49</volume><issue>8</issue><spage>1537</spage><epage>1543</epage><pages>1537-1543</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5‐fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermographic cooling was taken as the criterion of operability. Initial chemotherapy was resumed after surgery up to a total of ten courses and followed by maintenance chemotherapy for a minimum of one year. Immunotherapy using I‐BCG‐F. Pasteur was routinely associated with the antimitotic agents. The median survival for our 15 patients has not been reached and exceeds 56 months. These results correspond to an obvious therapeutic benefit compared with recent attempts in which similar chemoimmunotherapy protocols were used; this benefit seems to be the consequence of the adaptation of the length of initial chemotherapy to the data given by plate‐thermography.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>7066861</pmid><doi>10.1002/1097-0142(19820415)49:8<1537::AID-CNCR2820490805>3.0.CO;2-E</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1982-04, Vol.49 (8), p.1537-1543 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_74010310 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic Agents - administration & dosage BCG Vaccine - administration & dosage Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - surgery Carcinoma - drug therapy Carcinoma - pathology Carcinoma - surgery Doxorubicin - administration & dosage Drug Evaluation Drug Therapy, Combination Fluorouracil - administration & dosage Humans Melphalan - administration & dosage Methotrexate - administration & dosage Middle Aged Thermography Time Factors Vincristine - administration & dosage |
| title | Initial chemoimmunotherapy in inflammatory carcinoma of the breast |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T13%3A24%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20chemoimmunotherapy%20in%20inflammatory%20carcinoma%20of%20the%20breast&rft.jtitle=Cancer&rft.au=Zylberberg,%20B.&rft.date=1982-04-15&rft.volume=49&rft.issue=8&rft.spage=1537&rft.epage=1543&rft.pages=1537-1543&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(19820415)49:8%3C1537::AID-CNCR2820490805%3E3.0.CO;2-E&rft_dat=%3Cproquest_cross%3E74010310%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15496680&rft_id=info:pmid/7066861&rfr_iscdi=true |